MBX Capital (formerly FundRx) is an early-stage venture capital firm that invests in deep health companies at the convergence of biology, chemistry, AI/ML, robotics, and clinical medicine. The firm collaborates with a distributed network of scientific and clinical experts to source and peer-review investments.
32% of their portfolio is in Healthcare. Deal activity decreased year-over-year (1 deal in the last 12 months vs 3 prior). Their most common stage is series-a (50% of deals). Average disclosed round size is $24.1M (across 20 rounds with reported amounts).
Portfolio
21
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Zeshan Muhammedi
Co-founder & Managing Partner
Gurdane Singh Bhutani
Partner
Lucy Reynales Mohan
Partner
Roland Quaye M.D
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Think Bioscience | Series A | $55M | Jan 2026 |
 Keebler | Unknown | $16M | Jan 2026 |
 Vivodyne | Series A | — | May 2025 |
 Keebler Health | Seed | $6M | Feb 2025 |
 Tidal Vision | Series B | $140M | Feb 2025 |
| PPersist | Series A | $12M | Jan 2025 |
| Vivodyne | Seed | — | Nov 2023 |
 Arine | Series B | $29M | Aug 2022 |
 Offor Health | Series A | $9M | Apr 2022 |
 Dezy | Series A | $6M | Jan 2022 |
 Dezy | Series A | $6M | Jan 2022 |
| SSmiles.ai | Series A | $23M | Jan 2022 |
| KKoneksa | Series B | $16M | Jan 2022 |
 IXLayer | Series A | $75M | Mar 2021 |
 Lucy Goods, Inc | Series A | $10M | Feb 2020 |
 Osmosis | Seed | $4M | Jun 2019 |
 AmacaThera | Series A | $10.3M | Jan 2019 |
 Freedom Bioscience | Seed | $10.5M | — |
 Macro Trials | Seed | $6M | — |
 Journey Colab | Seed | $3M | — |
 JUNIPER GENOMICS | Seed | $4.6M | — |
 Atlas Health | Series A | $40M | — |
Top Co-Investors
Last updated: 7 October 2026